These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 2203503)
1. Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare". Mackintosh J; Simes J; Raghavan D; Pearson B Br J Urol; 1990 Jul; 66(1):88-93. PubMed ID: 2203503 [TBL] [Abstract][Full Text] [Related]
2. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P). Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591 [TBL] [Abstract][Full Text] [Related]
3. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer. Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827 [TBL] [Abstract][Full Text] [Related]
4. [Bone scintigraphy, plasma ALP, TAP and PAP in patients with prostatic cancer]. Imamura A; Hoshi H; Jinnouchi S; Samejima M; Watanabe K Kaku Igaku; 1988 Feb; 25(2):177-81. PubMed ID: 3386031 [No Abstract] [Full Text] [Related]
6. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459 [TBL] [Abstract][Full Text] [Related]
7. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?]. Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988 [TBL] [Abstract][Full Text] [Related]
8. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. Killian CS; Emrich LJ; Vargas FP; Yang N; Wang MC; Priore RL; Murphy GP; Chu TM J Natl Cancer Inst; 1986 Feb; 76(2):179-85. PubMed ID: 2418245 [TBL] [Abstract][Full Text] [Related]
9. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group]. Taue R; Kanayama H; Kagawa S Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358 [TBL] [Abstract][Full Text] [Related]
10. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Gerber G; Chodak GW Urology; 1991 May; 37(5):418-22. PubMed ID: 2024388 [TBL] [Abstract][Full Text] [Related]
11. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer. Wolff JM; Ittel T; Boeckmann W; Reinike T; Habib FK; Jakse G Eur Urol; 1996; 30(3):302-6. PubMed ID: 8931961 [TBL] [Abstract][Full Text] [Related]
12. Skeletal alkaline phosphatase: a marker for individual follow-up in patients with advanced prostatic cancer. Wechsel HW; Petri E; Bichler KH Urol Int; 1997; 58(2):80-3. PubMed ID: 9096267 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Bertagna C; De Géry A; Hucher M; François JP; Zanirato J Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827 [TBL] [Abstract][Full Text] [Related]
14. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein]. Shinoda I Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555 [TBL] [Abstract][Full Text] [Related]
15. A reappraisal of serial isotope bone scans in prostate cancer. O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607 [TBL] [Abstract][Full Text] [Related]
16. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit. Kida T; Higuchi Y Oncology; 1983; 40(5):346-50. PubMed ID: 6621997 [TBL] [Abstract][Full Text] [Related]
17. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase. Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213 [TBL] [Abstract][Full Text] [Related]
18. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166 [TBL] [Abstract][Full Text] [Related]
19. The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer. Killian CS; Vargas FP; Pontes EJ; Beckley S; Slack NH; Murphy GP; Chu TM Prostate; 1981; 2(2):187-206. PubMed ID: 7301655 [TBL] [Abstract][Full Text] [Related]
20. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Saito S; Tachibana M; Murai M J Urol; 1997 May; 157(5):1736-9. PubMed ID: 9112516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]